Amgen Confirms US Aflibercept Filing As Regeneron Awaits Biocon Trial Fate
Key Exclusivity In May 2024, But Feeling Is That H2 2025 Launch More Likely
Amgen has thrown its hat in the ring to launch a US biosimilar to Regeneron’s Eylea eye-disease blockbuster, as all eyes remain on the outcome of a key patent-infringement trial between Biocon and the originator.
